X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (40453) 40453
Newsletter (162) 162
Magazine Article (124) 124
Book Chapter (61) 61
Newspaper Article (21) 21
Book / eBook (19) 19
Conference Proceeding (7) 7
Dissertation (7) 7
Transcript (7) 7
Book Review (5) 5
Reference (5) 5
Web Resource (5) 5
Government Document (3) 3
Publication (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (36405) 36405
male (20771) 20771
female (20302) 20302
immunosuppressive agents - therapeutic use (19714) 19714
immunosuppressive agents - adverse effects (19022) 19022
adult (15067) 15067
middle aged (14727) 14727
transplantation (11406) 11406
treatment outcome (8847) 8847
immunosuppressive agents - administration & dosage (7711) 7711
surgery (7142) 7142
aged (7075) 7075
immunology (6343) 6343
immunosuppressive agents (5985) 5985
adolescent (5603) 5603
risk factors (5348) 5348
retrospective studies (5030) 5030
animals (4839) 4839
kidney transplantation (4573) 4573
time factors (4559) 4559
child (4367) 4367
therapy (4292) 4292
immunosuppression (4210) 4210
drug therapy, combination (4098) 4098
cyclosporine (4006) 4006
tacrolimus (3584) 3584
follow-up studies (3521) 3521
kidney transplantation - adverse effects (3484) 3484
graft rejection - prevention & control (3429) 3429
cyclosporine - adverse effects (3368) 3368
cyclosporine - therapeutic use (3200) 3200
young adult (3118) 3118
recipients (3000) 3000
pharmacology & pharmacy (2877) 2877
care and treatment (2748) 2748
health aspects (2713) 2713
immunotherapy (2664) 2664
immunosuppressive agents - pharmacology (2641) 2641
kidneys (2532) 2532
gastroenterology & hepatology (2528) 2528
tacrolimus - therapeutic use (2513) 2513
mycophenolic acid - analogs & derivatives (2441) 2441
tacrolimus - adverse effects (2356) 2356
urology & nephrology (2330) 2330
prospective studies (2327) 2327
child, preschool (2294) 2294
disease (2284) 2284
analysis (2260) 2260
hematology (2227) 2227
medicine & public health (2208) 2208
kidney transplantation - immunology (2198) 2198
dermatology (2146) 2146
drug therapy (2119) 2119
rheumatology (2102) 2102
transplantation, homologous (1990) 1990
medicine, general & internal (1987) 1987
oncology (1908) 1908
patients (1889) 1889
research (1879) 1879
pediatrics (1877) 1877
mycophenolic acid - therapeutic use (1874) 1874
recurrence (1874) 1874
mycophenolate-mofetil (1866) 1866
azathioprine - therapeutic use (1831) 1831
dose-response relationship, drug (1809) 1809
biopsy (1806) 1806
children (1804) 1804
liver transplantation (1755) 1755
azathioprine (1753) 1753
efficacy (1751) 1751
prognosis (1736) 1736
graft rejection - immunology (1735) 1735
graft survival (1710) 1710
incidence (1708) 1708
antibodies, monoclonal - therapeutic use (1707) 1707
calcineurin inhibitors (1699) 1699
risk (1688) 1688
organ transplant recipients (1646) 1646
corticosteroids (1643) 1643
immunocompromised host (1615) 1615
immunosuppressive agents - pharmacokinetics (1615) 1615
cyclosporine - administration & dosage (1591) 1591
double-blind (1576) 1576
safety (1539) 1539
liver (1531) 1531
cancer (1527) 1527
tacrolimus - administration & dosage (1524) 1524
transplants & implants (1522) 1522
drug administration schedule (1489) 1489
graft rejection (1481) 1481
diagnosis (1475) 1475
azathioprine - adverse effects (1472) 1472
renal-transplantation (1471) 1471
sirolimus (1458) 1458
abridged index medicus (1455) 1455
infection (1436) 1436
sirolimus - therapeutic use (1410) 1410
infant (1386) 1386
liver transplantation - adverse effects (1374) 1374
mice (1368) 1368
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (38117) 38117
German (878) 878
French (712) 712
Spanish (557) 557
Japanese (444) 444
Chinese (167) 167
Italian (147) 147
Portuguese (118) 118
Russian (115) 115
Polish (103) 103
Hungarian (62) 62
Dutch (51) 51
Danish (48) 48
Norwegian (45) 45
Czech (34) 34
Croatian (22) 22
Swedish (19) 19
Hebrew (17) 17
Finnish (15) 15
Korean (13) 13
Serbian (9) 9
Bulgarian (8) 8
Romanian (7) 7
Turkish (6) 6
Lithuanian (5) 5
Slovak (3) 3
Icelandic (2) 2
Bosnian (1) 1
Slovenian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of hepatology, ISSN 0168-8278, 2012, Volume 58, Issue 4, pp. 792 - 800
Summary Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other co-morbidities. Drug... 
Gastroenterology and Hepatology | Boceprevir | Hepatitis C virus infection | Telaprevir | Pharmacokinetics | Drug interactions | CHRONIC HEPATITIS-C | GASTROENTEROLOGY & HEPATOLOGY | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hepatitis C, Chronic - metabolism | Antiviral Agents - pharmacokinetics | Hypnotics and Sedatives - adverse effects | Humans | Hypnotics and Sedatives - administration & dosage | Drug Interactions | Hypoglycemic Agents - administration & dosage | Drug Therapy, Combination | Immunosuppressive Agents - administration & dosage | Cardiovascular Agents - administration & dosage | Anti-Infective Agents - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Opiate Substitution Treatment - adverse effects | Buprenorphine - administration & dosage | Anti-Infective Agents - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Antiviral Agents - adverse effects | Buprenorphine - adverse effects | Antidepressive Agents - administration & dosage | Immunosuppressive Agents - adverse effects | Methadone - administration & dosage | Methadone - adverse effects | Antidepressive Agents - adverse effects | Cardiovascular Agents - adverse effects | Hypoglycemic Agents - adverse effects | Hepatitis C virus
Journal Article
European Journal of Internal Medicine, ISSN 0953-6205, 2014, Volume 25, Issue 10, pp. 900 - 908
Abstract Background Patients with chronic diseases often receive multiple medications and are associated with increased vulnerability to medication errors.... 
Internal Medicine | Safety management/organization and administration | High-alert medications | Patient safety | Chronic patient | Medication errors/prevention and control | EMERGENCY-DEPARTMENT VISITS | HOSPITAL ADMISSIONS | UNIT | ADVERSE DRUG EVENTS | SAFETY | RISK | PREVALENCE | CARE | OLDER PERSONS | MEDICINE, GENERAL & INTERNAL | PRESCRIPTIONS | Digoxin - adverse effects | Drug-Related Side Effects and Adverse Reactions - prevention & control | Antipsychotic Agents - adverse effects | Humans | Sodium Potassium Chloride Symporter Inhibitors - adverse effects | Mineralocorticoid Receptor Antagonists - adverse effects | Amiodarone - analogs & derivatives | Adrenal Cortex Hormones - adverse effects | Amiodarone - adverse effects | Cytostatic Agents - adverse effects | Methotrexate - adverse effects | Analgesics, Opioid - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anticonvulsants - adverse effects | Anti-Arrhythmia Agents - adverse effects | Adrenergic beta-Antagonists - adverse effects | Immunosuppressive Agents - adverse effects | Benzodiazepines - adverse effects | Spironolactone - analogs & derivatives | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Spironolactone - adverse effects | Chronic Disease - drug therapy | Platelet Aggregation Inhibitors - adverse effects | Drugs | Chronic diseases
Journal Article
Drug safety, ISSN 0114-5916, 2000, Volume 23, Issue 5, pp. 429 - 448
... abnormalities.The newer 5-ASA agents were developed to deliver the active ingredient of sulfasalazine while minimising adverse effects... 
Mercaptopurine, general | Inflammatory bowel disease, treatment | Salicylates, general | Ciprofloxacin, general | Cyclosporin, general | Sulfasalazine, general | Azathioprine, general | Antibacterials, general | Metronidazole, general | Methotrexate, general | Tacrolimus, general | Immunomodulators, general | Mycophenolate mofetil, general | Aminosalicylic acid, general | Corticosteroids, general | RHEUMATOID-ARTHRITIS | LONG-TERM | RENAL-ALLOGRAFT RECIPIENTS | GLUCOCORTICOID-INDUCED OSTEOPOROSIS | ACTIVE CROHNS-DISEASE | RESISTANT ULCERATIVE-COLITIS | 5-AMINOSALICYLIC ACID | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | TOXICOLOGY | PLACEBO-CONTROLLED TRIAL | MYCOPHENOLATE-MOFETIL | Anti-Infective Agents - pharmacology | Humans | Immunosuppressive Agents - therapeutic use | Male | Sulfasalazine - pharmacology | Adrenal Cortex Hormones - therapeutic use | Prodrugs - metabolism | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Female | Immunosuppressive Agents - pharmacology | Inflammatory Bowel Diseases - drug therapy | Sulfasalazine - therapeutic use | Anti-Infective Agents - adverse effects | Mesalamine - adverse effects | Adrenal Cortex Hormones - pharmacology | Anti-Infective Agents - therapeutic use | Pregnancy | Adrenal Cortex Hormones - adverse effects | Gastrointestinal Agents - pharmacology | Mesalamine - pharmacology | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Gastrointestinal Agents - therapeutic use | Mesalamine - therapeutic use | Immunosuppressive Agents - adverse effects | Gastrointestinal Agents - adverse effects | Sulfasalazine - adverse effects
Journal Article
PloS one, ISSN 1932-6203, 2018, Volume 13, Issue 6, p. e0198184
Background Many patients with immune thrombocytopenia (ITP) may require special attention and long-term treatment. Little is known on the efficacy and... 
AUTOIMMUNE THROMBOCYTOPENIA | TREATMENT OPTIONS | ADULT PATIENTS | INTRAVENOUS GAMMA-GLOBULIN | MANAGEMENT | ANTI-D | MEDICAL THERAPY | SAFETY | PURPURA | ROMIPLOSTIM | MULTIDISCIPLINARY SCIENCES | Prednisolone - adverse effects | Azathioprine - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Recombinant Fusion Proteins - adverse effects | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Immunoglobulins, Intravenous - adverse effects | Child, Preschool | Dexamethasone - adverse effects | Male | Dapsone - therapeutic use | Purpura, Thrombocytopenic, Idiopathic - drug therapy | Receptors, Fc - therapeutic use | Splenectomy | Young Adult | Aged, 80 and over | Child | Rituximab - adverse effects | Purpura, Thrombocytopenic, Idiopathic - surgery | Combined Modality Therapy | Remission Induction | Cyclosporine - therapeutic use | Dexamethasone - therapeutic use | Immunoglobulins, Intravenous - therapeutic use | Rho(D) Immune Globulin - adverse effects | Cyclosporine - adverse effects | Adolescent | Rho(D) Immune Globulin - therapeutic use | Dapsone - adverse effects | Benzoates - adverse effects | Recombinant Fusion Proteins - therapeutic use | Thrombopoietin - therapeutic use | Purpura, Thrombocytopenic, Idiopathic - therapy | Rituximab - therapeutic use | Adult | Female | Prednisolone - therapeutic use | Retrospective Studies | Drug Therapy, Combination | Drug Resistance | Pyrazoles - adverse effects | Hydrazines - therapeutic use | Treatment Outcome | Thrombopoietin - adverse effects | Immunosuppressive Agents - adverse effects | Aged | Azathioprine - adverse effects | Hydrazines - adverse effects | Thrombocytopenic purpura | Clinical trials | Treatment outcome | Care and treatment | Analysis | Drugs | Thrombocytopenia | Therapy | Immunoglobulins | Dexamethasone | Intravenous administration | Medical treatment | Patients | Immunosuppressive agents | Bleeding | Medicine | Remission | Clinical medicine | Azathioprine | Drug dosages | Prednisolone
Journal Article
Biology of blood and marrow transplantation, ISSN 1083-8791, 2013, Volume 19, Issue 1, pp. 117 - 122
Abstract Fifty patients with high-risk hematologic malignancies, underwent an unmanipulated haploidentical bone marrow transplantation (BMT), followed by... 
Hematology, Oncology and Palliative Medicine | Haploidentical transplantations | Acute leukemia | HLA | Posttransplantation cyclophosphamide | Allogeneic stem cell transplant | MORTALITY | IMMUNOLOGY | RECIPIENTS | VERSUS-HOST-DISEASE | TRANSPLANTATION | REDUCED-INTENSITY | ACUTE-LEUKEMIA | HIGH-RISK | HAPLOTYPE | OUTCOMES | STEM-CELL TRANSPLANTATION | HEMATOLOGY | BLOOD | Hematologic Neoplasms - therapy | Whole-Body Irradiation | Cyclophosphamide - administration & dosage | Follow-Up Studies | Myeloablative Agonists - adverse effects | Thiotepa - administration & dosage | Hematologic Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Busulfan - administration & dosage | Cyclophosphamide - adverse effects | Transplantation, Homologous | Graft vs Host Disease - mortality | Antineoplastic Agents - adverse effects | Bone Marrow Transplantation | Adult | Female | Retrospective Studies | Graft vs Host Disease - etiology | Immunosuppressive Agents - administration & dosage | Acute Disease | Busulfan - adverse effects | Vidarabine - adverse effects | Survival Rate | Vidarabine - analogs & derivatives | Disease-Free Survival | Adolescent | Myeloablative Agonists - administration & dosage | Graft vs Host Disease - prevention & control | Immunosuppressive Agents - adverse effects | Aged | Vidarabine - administration & dosage | Transplantation Conditioning | Chronic Disease | Thiotepa - adverse effects | Antimitotic agents | Pneumonia | Cyclophosphamide | Bacterial pneumonia | Mortality | Bone marrow | Transplantation | Antineoplastic agents | Cancer
Journal Article
Leukemia, ISSN 0887-6924, 12/2008, Volume 22, Issue 12, pp. 2247 - 2256
...) and its effect on bone remodeling and angiogenesis in relapsed/refractory myeloma. Bortezomib (1.0mg/m(2)) was given on days 1, 4, 8, 11, oral melphalan... 
MULTIPLE-MYELOMA | SURVIVAL | CELLS | multiple myeloma | RESORPTION | MARROW | melphalan | angiogenesis | MARKERS | PREDNISONE | bone metabolism | SERUM CONCENTRATIONS | thalidomide | ONCOLOGY | DISEASE | RECEPTOR ACTIVATOR | bortezomib | HEMATOLOGY | Neovascularization, Physiologic - drug effects | Recurrence | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Male | Antineoplastic Agents, Alkylating - administration & dosage | Bone Remodeling - drug effects | Bone and Bones - drug effects | Antineoplastic Agents, Hormonal - adverse effects | Multiple Myeloma - drug therapy | Melphalan - adverse effects | Bone and Bones - metabolism | Aged, 80 and over | Adult | Female | Boronic Acids - administration & dosage | Immunosuppressive Agents - administration & dosage | Multiple Myeloma - physiopathology | Biomarkers - metabolism | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Cytokines - metabolism | Antineoplastic Agents, Hormonal - administration & dosage | Survival Rate | Thalidomide - administration & dosage | Multiple Myeloma - metabolism | Melphalan - administration & dosage | Pyrazines - adverse effects | Immunosuppressive Agents - adverse effects | Aged | Antineoplastic Agents, Alkylating - adverse effects | Antimitotic agents | Multiple myeloma | Physiological aspects | Genetic aspects | Dosage and administration | Drug therapy, Combination | Neovascularization | Research | Drug therapy | Antineoplastic agents | Health aspects | Index Medicus
Journal Article
Seminars in diagnostic pathology, ISSN 0740-2570, 2014, Volume 31, Issue 2, pp. 165 - 175
Journal Article